Author

Gaby Tresch

Institution: Molecular Partners (Switzerland)

Observed institution: Molecular Partners (Switzerland)

OpenAlex ID: A5063947614

Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate

2017 · H. Kaspar Binz, Talitha R. Bakker, et al. · mAbs · 68

Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID‐19: A phase 2a, open‐label, single‐dose escalation study

2022 · Manon L. M. Prins, Johan L. van der Plas, et al. · British Journal of Clinical Pharmacology · 10

A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer After Prior Trastuzumab and Pertuzumab

2022 · Stefanie Fischer, Thorsten O. Götze, et al. · JCO Precision Oncology · 6

Works count: 3

Citation count: 84

H-index: 3

I10-index: 2